(Q35066804)

English

Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

0 references

Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

systematic review

1 reference

based on heuristic

inferred from title

sexual dysfunction

1 reference

based on heuristic

inferred from title

major depressive disorder

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Gerald Gartlehner

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Megan Van Noord

object named as

Megan Van Noord

7

0 references

Richard A. Hansen

object named as

Richard A Hansen

6

0 references

Bradley N. Gaynes

object named as

Bradley N Gaynes

9

0 references

author name string

Ursula Reichenpfader

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Laura C Morgan

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Amy Greenblatt

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Barbara Nussbaumer

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Linda Lux

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

19-31

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Cross-national epidemiology of DSM-IV major depressive episode

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

The top prescription drugs of 2011 in the United States: antipsychotics and antidepressants once again lead CNS therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Antidepressant-induced sexual dysfunction

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

A Survey of Sexual Side Effects Among Severely Mentally Ill Patients Taking Psychotropic Medications: Impact on Compliance

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Semi-automating the manual literature search for systematic reviews increases efficiency

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Evaluating non-randomised intervention studies

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder

2 references

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo in Outpatients with Major Depression

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Fluoxetine in the prevention of depressive recurrences: a double-blind study.

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Extended-release venlafaxine in relapse prevention for patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Adverse events in users of sertraline: results from an observational study in psychiatric practice in The Netherlands

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0129-4

21 January 2018

Sexual side effects of antidepressants

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind comparison of bupropion and fluoxetine in depressed outpatients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mirtazapine compared with paroxetine in major depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of antidepressants on sexual functioning in depressed patients: a review.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sexual dysfunction before antidepressant therapy in major depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mirtazapine versus other antidepressive agents for depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance Phase Efficacy of Sertraline for Chronic Depression A Randomized Controlled Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of sexual dysfunction among newer antidepressants.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of mental illness and psychotropic medications on sexual functioning: the evidence and management

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sertraline versus other antidepressive agents for depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sexual problems in healthy and depressed persons

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Newer antidepressants: a comparison of tolerability in general practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Citalopram versus other anti-depressive agents for depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40264-013-0129-4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35066804&oldid=2197211046"